Exosomal MicroRNA-107 Reverses Chemotherapeutic Drug Resistance of Gastric Cancer Cells Through HMGA2/mTOR/P-gp Pathway

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Dec 3

PMID 34856955

Citations 17

Authors

Lu Jiang

Yan Zhang

Linghui Guo

Chaoyang Liu

Pan Wang

Weihong Ren

Affiliations

Soon will be listed here.

Abstract

Background: RNA cargo in exosomes, especially microRNAs (miRNAs), play an important role in the chemotherapy drug resistance of human cancers. However, the role and mechanism of exosomal miR-107 on multidrug resistance of gastric cancer cells was still not clear. In this study, we sought to explore whether exosomal miR-107 could reverse the resistance of gastric cancer cells to the chemotherapy drugs.

Methods: We extracted exosomes from sensitive (SGC-7901, MGC-803) and resistant (SGC-7901/5-FU) gastric cancer cells by ultracentrifugation and the isolated exosomes were identified using transmission electron microscopy (TEM) and dynamic light scattering analysis (DLS). The expression of miR-107 and high mobility group A2 (HMGA2) were detected by real-time quantitative PCR (RT-qPCR). MTT assay was used to investigate the effect of exosomes on gastric cancer cells growth in vitro. The uptake of exosomes by recipient cells were observed using a fluorescence microscope. The predicted target relationship between miR-107 and HMGA2 was verified by gauss-luciferase reporter assay. The expression of HMGA2, p-mTOR/mTOR, P-gp and other exosomal indicated marker proteins was detected by western blot.

Results: Our results indicated that the isolated exosomes were typically cup-like lipid bilayer membranes structure. SGC-7901/5-FU cells were cross-resistant to chemotherapy drug cisplatin (CDDP), and the sensitive cells-secreted exosomes drastically reversed the resistance of the resistant GC cells to the chemotherapeutic drugs, which was verified by exosomal inhibitor GW4896. Mechanistically, the reversal effect was mainly mediated by exosome-secreted miR-107 through downregulating the expression of target molecular HMGA2 and inhibiting HMGA2/mTOR/P-gp pathway, which were supported by results from luciferase reporter assay and rescue assay.

Conclusions: These findings demonstrated that exosome-transmitted miR-107 significantly enhanced the sensitivity of resistant gastric cancer cells to chemotherapeutic agents by mediating the HMGA2/mTOR/P-gp axis and exosomal miR-107 may be a novel target in gastric cancers treatment.

Citing Articles

A novel mechanism in regulating drug sensitivity, growth, and apoptosis of bortezomib-resistant multiple myeloma cells: the USP4/KLF2/HMGA2 cascade.

Liu Z, Li X, He Y, Xie F, Zhang Y, Huang M J Orthop Surg Res. 2025; 20(1):220.

PMID: 40022160 PMC: 11871775. DOI: 10.1186/s13018-025-05537-1.

Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.

Zhang H, Wu B, Wang Y, Du H, Fang L Molecules. 2025; 30(3).

PMID: 39942602 PMC: 11819960. DOI: 10.3390/molecules30030498.

Exploring extracellular RNA as drivers of chemotherapy resistance in cancer.

Khan Y, Hussain M, Ramalingam P, Fatima R, Maqbool M, Ashique S Mol Biol Rep. 2025; 52(1):142.

PMID: 39836259 DOI: 10.1007/s11033-025-10263-2.

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.

Emerging role of exosomes in cancer therapy: progress and challenges.

Li J, Wang J, Chen Z Mol Cancer. 2025; 24(1):13.

PMID: 39806451 PMC: 11727182. DOI: 10.1186/s12943-024-02215-4.

References

Vignali R, Marracci S . HMGA Genes and Proteins in Development and Evolution. Int J Mol Sci. 2020; 21(2). PMC: 7013770. DOI: 10.3390/ijms21020654. View

Cao C, Wang B, Tang J, Zhao J, Guo J, Guo Q . Circulating exosomes repair endothelial cell damage by delivering miR-193a-5p. J Cell Mol Med. 2020; 25(4):2176-2189. PMC: 7882992. DOI: 10.1111/jcmm.16202. View

Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T . Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018; 37(1):52. PMC: 5846230. DOI: 10.1186/s13046-018-0677-7. View

Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R . Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep. 2012; 27(6):1759-64. DOI: 10.3892/or.2012.1709. View

Ma Y, Yuwen D, Chen J, Zheng B, Gao J, Fan M . Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy. Int J Nanomedicine. 2019; 14:8121-8132. PMC: 6790351. DOI: 10.2147/IJN.S221383. View

Li M, Lu Y, Xu Y, Wang J, Zhang C, Du Y . Horizontal transfer of exosomal CXCR4 promotes murine hepatocarcinoma cell migration, invasion and lymphangiogenesis. Gene. 2018; 676:101-109. DOI: 10.1016/j.gene.2018.07.018. View

Yang Y, Zhang P, Zhao Y, Yang J, Jiang G, Fan J . Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther. 2015; 17(5):515-25. PMC: 4910912. DOI: 10.1080/15384047.2015.1095405. View

Wang Y, Mao J, Wang J, Xu M . MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2. Technol Cancer Res Treat. 2020; 19:1533033820928143. PMC: 7325540. DOI: 10.1177/1533033820928143. View

Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B . Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019; 459:122-134. DOI: 10.1016/j.canlet.2019.05.035. View

10.

Yang S, Gu Y, Wang G, Hu Q, Chen S, Wang Y . HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling. Int J Mol Med. 2019; 44(2):427-436. PMC: 6605696. DOI: 10.3892/ijmm.2019.4229. View

11.

Lin H, Zhang L, Zhang C, Liu P . Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020; 24(16):8930-8941. PMC: 7417713. DOI: 10.1111/jcmm.15524. View

12.

Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q . Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019; 38(1):81. PMC: 6377760. DOI: 10.1186/s13046-019-1095-1. View

13.

Pastan I, Gottesman M . Multidrug resistance. Annu Rev Med. 1991; 42:277-86. DOI: 10.1146/annurev.me.42.020191.001425. View

14.

He Z, Li Z, Zhang X, Yin K, Wang W, Xu Z . MiR-422a regulates cellular metabolism and malignancy by targeting pyruvate dehydrogenase kinase 2 in gastric cancer. Cell Death Dis. 2018; 9(5):505. PMC: 5938701. DOI: 10.1038/s41419-018-0564-3. View

15.

Mashouri L, Yousefi H, Aref A, Ahadi A, Molaei F, Alahari S . Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019; 18(1):75. PMC: 6444571. DOI: 10.1186/s12943-019-0991-5. View

16.

Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang Z . Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 2018; 120(6):9656-9666. DOI: 10.1002/jcb.28244. View

17.

Liang Y, Zhu D, Hou L, Wang Y, Huang X, Zhou C . MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020; 122(5):705-714. PMC: 7054533. DOI: 10.1038/s41416-019-0703-3. View

18.

Jiang L, Wang P, Sun Y, Wu Y . Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019; 38(1):265. PMC: 6580523. DOI: 10.1186/s13046-019-1251-7. View

19.

Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang S . Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. J Cancer Res Clin Oncol. 2015; 142(2):389-99. DOI: 10.1007/s00432-015-2036-9. View

20.

Liu X, Yidayitula Y, Zhao H, Luo Y, Ma X, Xu M . LncRNA LINC00152 promoted glioblastoma progression through targeting the miR-107 expression. Environ Sci Pollut Res Int. 2018; 25(18):17674-17681. DOI: 10.1007/s11356-018-1784-x. View